Davis PE, et al. Presentation and diagnosis of tuberous sclerosis complex in infants. Pediatrics 2017; 140:e20164040. doi: 10.1542/peds.2016-4040

• PubMed
Davis PE, Presentation and diagnosis of tuberous sclerosis complex in infants. Pediatrics 2017; 140:e20164040. doi: 10.1542/peds.2016-4040 )| false
• Search Google Scholar
• Export Citation

Bissler JJ, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358:140–151. doi: 10.1056/NEJ-Moa063564

• PubMed
Bissler JJ, Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358:140–151. doi: 10.1056/NEJ-Moa063564 )| false
• Search Google Scholar
• Export Citation

Bissler JJ, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381:817–824. doi: 10.1016/S0140-6736(12)61767-X

• PubMed
Bissler JJ, Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381:817–824. doi: 10.1016/S0140-6736(12)61767-X )| false
• Search Google Scholar
• Export Citation

Franz DN, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381:125–132. doi: 10.1016/S0140-6736(12)61134-9

• PubMed
Franz DN, Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381:125–132. doi: 10.1016/S0140-6736(12)61134-9 )| false
• Search Google Scholar
• Export Citation

French JA, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): A phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016; 388:2153–2163. doi: 10.1016/S0140-6736(16)31419-2

• PubMed
French JA, Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): A phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016; 388:2153–2163. doi: 10.1016/S0140-6736(16)31419-2 )| false
• Search Google Scholar
• Export Citation

Kingswood JC, et al. Review of the tuberous sclerosis renal guidelines from the 2012 Consensus Conference: Current data and future study. Nephron 2016; 134:51–58. doi: 10.1159/000448293

• PubMed
Kingswood JC, Review of the tuberous sclerosis renal guidelines from the 2012 Consensus Conference: Current data and future study. Nephron 2016; 134:51–58. doi: 10.1159/000448293 )| false
• Search Google Scholar
• Export Citation

Siroky BJ, et al. Improvement in renal cystic disease of tuberous sclerosis complex after treatment with mammalian target of rapamycin inhibitor. J Pediatr 2017; 187:318-322.e2. doi: 10.1016/j.jpeds.2017.05.015

• PubMed
Siroky BJ, Improvement in renal cystic disease of tuberous sclerosis complex after treatment with mammalian target of rapamycin inhibitor. J Pediatr 2017; 187:318-322.e2. doi: 10.1016/j.jpeds.2017.05.015 )| false
• Search Google Scholar
• Export Citation

Nechama M, et al. Rapamycin and dexamethasone during pregnancy prevent tuberous sclerosis complex-associated cystic kidney disease. JCI Insight 2020; 5:e136857. doi: 10.1172/jci.insight.136857

• PubMed
Nechama M, Rapamycin and dexamethasone during pregnancy prevent tuberous sclerosis complex-associated cystic kidney disease. JCI Insight 2020; 5:e136857. doi: 10.1172/jci.insight.136857 )| false
• Search Google Scholar
• Export Citation

Volovelsky O, et al. Hamartin regulates cessation of mouse nephrogenesis independently of mTOR. Proc Natl Acad Sci USA 2018; 115:5998–6003. doi: 10.1073/pnas.1712955115

• PubMed
Volovelsky O, Hamartin regulates cessation of mouse nephrogenesis independently of mTOR. Proc Natl Acad Sci USA 2018; 115:5998–6003. doi: 10.1073/pnas.1712955115 )| false
• Search Google Scholar
• Export Citation